Pinsent Masons advises 4D Pharma PLC on innovative move to NASDAQ

28 Oct 2020 | 10:31 am | 1 min. read

Multinational law firm Pinsent Masons has advised AIM listed biotech company 4D Pharma plc (4D) on its acquisition of Longevity Acquisition Corporation, a special-purpose acquisition company (SPAC) listed on NASDAQ. Upon completion of the transaction 4D will apply for its American Depositary Shares to be admitted to trading on NASDAQ.

4D, who are leading the development of live biotherapeutic products, are believed to be the first UK biotech to make the move to NASDAQ via the acquisition of a SPAC, breaking new ground for UK listed biotechs. The Company will also maintain its current listing on AIM.

With 4D acquiring the SPAC in order to inherit its listing on NASDAQ, they are able to by-pass the usual nine month lead-in time foreign issuers have to contend with when seeking a direct listing on NASDAQ.

The Pinsent Masons team was led by Charles Waddell and Sunjay Malhotra with assistance from Julian Stanier, Amy Moore and Nathalie Goetsches; US securities advice was provided by Roberta Markovina and Beatrice Kelly; Eloise Walker, Jamie Robson and Daniel Place assisted on UK tax matters; and Fleur Benns and James Sullivan-Tailyour provided assistance with regards to 4D’s share option plans.

Commenting on the transaction, lead partner at Pinsent Masons Charles Waddell said:

"We have enjoyed working with 4D for a number of years, they are at the cutting edge of live biotherapeutic products and this transaction is an important step in their future development and access to key to international markets.

Given the number of European biotechs that covet a move to NASDAQ, and notwithstanding the complex financing structures of SPACs, this deal highlights that there is an alternative route to the US markets. It is therefore unlikely to be the last biotech we see looking at SPACs to access the deep pool of sophisticated investors in the US."

Latest press releases

Show me all press releases

Pinsent Masons builds out its Luxembourg office with the hire of funds specialist Dr Jan Saalfrank LLM

Pinsent Masons builds out its Luxembourg office with the hire of funds specialist Dr Jan Saalfrank LLM

Pinsent Masons advises SUSI Partners on the launch of its Southeast Asian Renewables platform

Multinationallaw firm Pinsent Masons has advised SUSI Partners and its Asia EnergyTransition Fund on the launch of a renewable energy platform to developlarge-scale renewable assets across Southeast Asia.

Pinsent Masons hires corporate partner in Melbourne

Multinational law firm Pinsent Masons has strengthened its corporate team in Australia with the recruitment of partner Andrew Fisken.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons hires corporate partner in Melbourne

Multinational law firm Pinsent Masons has strengthened its corporate team in Australia with the recruitment of partner Andrew Fisken.

Pinsent Masons advises Alveo on its sale to Symphony Technology Group

Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).

Pinsent Masons advises Statkraft on landmark partnership with Copenhagen Infrastructure Partners 

Multinational law firm Pinsent Masons has advised Statkraft on the sale of a 50% stake in their Irish offshore wind portfolio to Copenhagen Infrastructure Partners’ fund, Copenhagen Infrastructure IV K/S, as part of its plans to develop up to 2.2 gigawatts of offshore wind in Ireland.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.